Trileptal Tablet, Film Coated
Product Images NDC 0078-0456

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Trileptal (NDC 0078-0456). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novartis Pharmaceuticals Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Oxcarbazepine Structural Formula. (Trileptal 01)

Chemical structure of oxcarbazepine, the active ingredient in Trileptal oral suspension. The diagram shows the molecular arrangement with characteristic rings and functional groups.*

FDA Label Image

Figure 1 Kaplan-meier Estimates Of Exit Rate By Treatment Group. (Trileptal 02)

Kaplan-Meier curve depicting exit rates over time from Day 2 to Day 11 in days, comparing treatment groups for oral suspension oxcarbazepine and placebo. The y-axis shows exit rate and the x-axis shows time on trial starting from Day 2 at 8 am. Statistical significance is noted with a log-rank test p-value of 0.0001.*

FDA Label Image

Figure 2 Kaplan-meier Estimates Of First Seizure Event Rate By Treatment Group. (Trileptal 03)

A Kaplan-Meier curve graph illustrating the seizure rate over time from first dose to first seizure in two treatment groups: oxcarbazepine and placebo. The graph shows the cumulative seizure rates on the y-axis and days on the x-axis, indicating a statistical difference (log-rank test p-value=0.046) in seizure occurrence between groups.*

FDA Label Image

Figure 3 Kaplan-meier Estimates Of Exit Rate By Treatment Group. (Trileptal 04)

A Kaplan-Meier plot graph depicting time to exit in days on the x-axis and exit rate on the y-axis for two treatment groups labeled HIGH (solid line) and LOW (dotted line). The graph includes a log-rank test with a p-value of 0.0001 indicating a statistical comparison between the groups.*

FDA Label Image

Figure 4 Kaplan-meier Estimates Of Exit Rate By Treatment Group. (Trileptal 05)

A Kaplan-Meier survival curve chart comparing time to exit between two treatment groups, labeled High and Low. The x-axis represents time to exit in days up to 130, and the y-axis shows exit rate from 0.0 to 1.0. The chart includes a log-rank test p-value of 0.0001, indicating a significant difference between the groups.*

FDA Label Image

Principal Display Panelpackage Label – 150 mgrx Only Ndc 0078-0456-05trileptal® (oxcarbazepine)100 Tabletspharmacist: Dispense With Medication Guide Attached Or Provided Separately. (Trileptal 06)

Label for Trileptal 150 mg tablets (oxcarbazepine) by Novartis Pharmaceuticals Corporation. The label includes the National Drug Code (NDC 0078-0456-05), quantity of 100 tablets, and indicates prescription use with a note to dispense with the medication guide. The label features the Novartis logo and barcode.*

FDA Label Image

Principal Display Panelpackage Label – 300 mgrx Only Ndc 0078-0337-05trileptal® (oxcarbazepine)100 Tabletspharmacist: Dispense With Medication Guide Attached Or Provided Separately. (Trileptal 07)

Trileptal 300 mg (oxcarbazepine) oral tablets label from Novartis Pharmaceuticals Corporation. The label indicates 100 tablets per container, prescription-only status, and instructions to dispense with medication guide attached or provided separately. The label includes storage instructions and manufacturer information.*

FDA Label Image

Principal Display Panelpackage Label – 600 mgrx Only Ndc 0078-0457-05trileptal® (oxcarbazepine)100 Tabletspharmacist: Dispense With Medication Guide Attached Or Provided Separately. (Trileptal 08)

Label for Trileptal 600 mg tablets (oxcarbazepine) by Novartis Pharmaceuticals Corporation. The label indicates a package containing 100 tablets with prescription only status. Instructions for pharmacists to dispense with the medication guide are included, along with storage and dosage information.*

FDA Label Image

Principal Display Panelpackage Label – 300 mg / 5 mLrx Only Ndc 0078-0357-52trileptal® Oral Suspension(oxcarbazepine)important: Shake Well Before Using.each 5 mL Contains 300 mg Oxcarbazepine.250 mLpharmacist: Dispense With Medication Guide Enclosed Or Provided Separately. (Trileptal 09)

Trileptal (oxcarbazepine) Oral Suspension 300 mg/5 mL in a 250 mL bottle package label from Novartis Pharmaceuticals Corporation. The green and white label includes dosing information, storage instructions, and a notice to shake well before use. It specifies pharmacist dispensing with medication guide enclosed or provided separately and notes use within 7 weeks of first opening.*

FDA Label Image

1a (Trileptal 0a)

Trileptal (oxcarbazepine) oral suspension packaging label showing a top-down view of a bottle cap with a press-to-open design. The label does not display dosage strength or additional information but suggests a pharmaceutical suspension product from Novartis Pharmaceuticals Corporation.*

FDA Label Image

1b (Trileptal 0b)

Trileptal suspension bottle, an oral dosage form of oxcarbazepine by Novartis Pharmaceuticals Corporation. The image shows a standard pharmaceutical bottle with a child-resistant cap, typical for liquid medications. No specific strength or volume is visible on the label in this image.*

FDA Label Image

1c (Trileptal 0c)

An instructional illustration of a syringe labeled with parts: 'Barrel' indicating the main body of the syringe with measurement markings, and 'Plunger' indicating the part used to draw in or expel fluid. The syringe is marked up to 10 mL.*

FDA Label Image

2d (Trileptal 0d)

An instructional illustration showing a hand holding a bottle and shaking it, indicated by motion lines near the bottle and cap. This likely depicts proper preparation or use of an oral suspension medication.*

FDA Label Image

2e (Trileptal 0e)

An instructional illustration showing a pair of hands removing or placing the tamper-evident seal on the neck of a bottle, with the bottle cap positioned next to the bottle. The bottle is likely related to an oral suspension medication.*

FDA Label Image

3f (Trileptal 0f)

An instructional illustration showing a hand holding a bottle being shaken, indicating the proper way to mix or shake a liquid medication before use.*

FDA Label Image

3g (Trileptal 0g)

An instructional illustration showing a hand using a syringe to withdraw liquid medication from a bottle. The image includes an arrow indicating the downward motion of the syringe into the bottle opening. It depicts part of the medication administration process for oral suspension products like Trileptal (oxcarbazepine).*

FDA Label Image

3h (Trileptal 0h)

An instructional illustration showing a hand holding a syringe positioned under an upside-down bottle, demonstrating the process of drawing liquid medication into the syringe by moving the plunger up and down. This image likely relates to dose measurement or administration for an oral suspension.*

FDA Label Image

3i (Trileptal 0i)

An instructional illustration showing the use of a dosing syringe to measure oral suspension medication from a bottle. It demonstrates drawing the liquid into the syringe to a specified dose level marked on the syringe barrel, with an inset magnifying the dose markings.*

FDA Label Image

3j (Trileptal 0j)

An instructional illustration showing a hand drawing liquid medication from a bottle into an oral syringe by inserting the syringe into the bottle and pulling the plunger. This depicts proper use of an oral syringe for measuring and administering liquid suspension medication.*

FDA Label Image

3k (Trileptal 0k)

An instructional illustration showing the oral suspension administration of Trileptal (oxcarbazepine). The image depicts a person taking the medication from a syringe and the preparation of the dose by dropping the suspension from the syringe into a cup.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.